News
Enteris BioPharma rebrands to MOD3 Pharma
March 12th, 2025 – Enteris BioPharma, a fully integrated contract development and manufacturing organization, today announced that the company is changing its name to MOD3 Pharma.
A wholly owned subsidiary of SWK Holdings Corp. (SWKH), MOD3 Pharma continues to build on its strong growth agenda by refocusing its service portfolio to supporting investigational drugs in the development of Orally Inhaled and Nasal Drug Products (OINDP).
Introducing the new MOD3 Pharma logo and value proposition.
Specifically supporting clients working within phases 1&2 of clinical trials, MOD3 Pharma’s capabilities include spray drying, semi-automated filling and assembly for single dose powder and liquid nasal systems, bi-dose and multidose nasal devices. This service proposition uniquely fills the gap for organizations needing early phase clinical supplies.
Dr Paul Shields, CEO of MOD3 Pharma, comments “Enteris BioPharma built its reputation by formulating peptide drugs as oral tablets, enabling innovative treatment opportunities for compounds that typically were delivered via another route.”
“In recent years we have utilized our expertise and experience to support clients navigating Phase 1&2 clinical trials in the OINDP space, especially for nasal sprays and increasingly for nasal powders. We have rapidly become a recognized global partner of choice in this area, and so it made perfect sense to create a new name that better reflects our core competency and the unique value we deliver to our clients.”
“It is our strong belief that our new name should come directly from what we do, how we do it and how it benefits our clients. We’re your catalyst to clinic. And, we help you complete Module 3 of your IND – it’s in our name! MOD3 Pharma”
About MOD3 Pharma
YOUR CATALYST TO CLINIC
MOD3 Pharma combines decades of CMC experience with a laser focus on Orally Inhaled and Nasal Drug Products (OINDP) to transform your investigational drug into a clinic ready product.
Operating from our GMP manufacturing facility in Boonton, New Jersey, USA, we bring our scientific, manufacturing and regulatory experience to your project to allow you to manage risk, mitigate delays and reduce costs, building quality into your product from the start, and accelerating its transition into the clinic.
Contact Details
Paul Shields, CEO MOD3 Pharma
Email: pshields@mod3pharma.com
